The worldwide incidence of non-melanoma skin cancer (NMSC) has risen dramatically over the last decades. Basal cell carcinoma (BCC) is by far the most common type of skin cancer. NMSC needs to be regarded as a chronic disease that has enormous implications for health care systems, as will be outlined in this thesis. Physicians will need to take these implications, including costs, into account.
Simone van der Geer-Rutten
Contact Us
Xstrahl’s XBeam has received FDA 510(k) Clearance for Use in the U.S. The XBeam technology streamlines radiotherapy treatment planning and simplifies patient workflow for treating skin cancer, benign diseases, and palliative care. Explore how this innovation enhances orthovoltage superficial radiotherapy (SRT) and electronic brachytherapy (eBt). With XBeam, you can calculate, protocol and export treatment plans for Xstrahl treatments with Radiant Aura and all other Xstrahl medical devices in the U.S. and worldwide.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will feature Radiant Aura at the American Society for Mohs Surgery (ASMS) Fundamentals of Mohs Surgery Annual Meeting, November 14-17, 2024 at the Royal Sonesta Galleria, Houston, TX.
Xstrahl to Attend VCS and ASDS Conferences in Orlando: The recent hurricanes have affected so many, and the team at Xstrahl hopes that you and your family are safe. Our hearts go out to everyone as they face this difficult time ahead. Prior to the hurricanes, Xstrahl committed to attending two conferences in Orlando, FL this week, and organizers of the conferences have confirmed that they will still be happening. If you are attending either conference in Orlando, please visit our team to say hello. We’d love to meet you.
